[Diagnostic importance of visken -- an adrenergic beta receptor blocking agent].
Among the newest beta-blocking agents visken is the one that either produces no or very little adverse inotropic effect. In some groups of patients with organic and neurotic cardiac disorders, screened as a result of a careful clinical examination, changes that occurred on the ECG with 12 leads following an intake of a single visken tablet (5 mg) were studied. Ingestion of visken was not seen to bring any improvement in the ECG findings in 88 per cent of 50 patients with organic disorders, most of whom had sclerosis of the coronary arteries and hypertensive disease attended by a high diastolic pressure. A thorough clinical examination of 70 patients presenting neurotic conditions helped to rule out any organic cardiac lesions, and in them the diastolic pressure did not exceed 95 mm Hg. The visken test showed that in 91 per cent of these cases the ECG returned back to normal and only in 1.5 per cent of them no changes could be observed. In both of the above groups the effect of visken was statistically significant (p less than 0.001). Repolarization derangements in the I and II leads among patients with organic lesions was observed 4 times as often as in the II and III leads. Among neurotic patients changes recorded in the II and III leads were twice as frequent as in the I and II leads.
D000293:Adolescent; D000328:Adult; D005117:Cardiac Complexes, Premature / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology; D003327:Coronary Disease / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology; D004562:Electrocardiography; D005260:Female; D006321:Heart / Q000503:physiopathology*; D006331:Heart Diseases / Q000175:diagnosis*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000175:diagnosis* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009497:Neurotic Disorders / Q000150:complications / Q000503:physiopathology; D010869:Pindolol
D010869:Pindolol
Diagnosticheskoe znachenie viskena - blokatora beta- adrenergicheskikh retseptorov?